share_log

Biodexa Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Biodexa Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Biodexa Pharmaceuticals | POS AM：修改註冊聲明表
美股sec公告 ·  04/30 18:10
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the completion of several significant corporate transactions and the filing of a post-effective amendment to a registration statement with the SEC. The company has entered into a License and Collaboration Agreement with Emtora Biosciences for the exclusive rights to eRapa, a pharmaceutical formulation of rapamycin, and has also acquired the compound tolimidone from Adhera Therapeutics, Inc. Additionally, Biodexa has completed an underwritten public offering, raising approximately $6.0 million. These strategic moves aim to strengthen Biodexa's product pipeline and financial position. The company's securities are traded on the NASDAQ Capital Market under the symbol 'BDRX.'
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the completion of several significant corporate transactions and the filing of a post-effective amendment to a registration statement with the SEC. The company has entered into a License and Collaboration Agreement with Emtora Biosciences for the exclusive rights to eRapa, a pharmaceutical formulation of rapamycin, and has also acquired the compound tolimidone from Adhera Therapeutics, Inc. Additionally, Biodexa has completed an underwritten public offering, raising approximately $6.0 million. These strategic moves aim to strengthen Biodexa's product pipeline and financial position. The company's securities are traded on the NASDAQ Capital Market under the symbol 'BDRX.'
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已宣佈完成幾項重大公司交易，並向美國證券交易委員會提交了註冊聲明的生效後修正案。該公司已與Emtora Biosciences簽訂了許可和合作協議，獲得雷帕黴素的藥物製劑eRapa的獨家權利，還從Adhera Therapeutics, Inc.收購了化合物託利米酮。此外，Biodexa已完成承保公開募股，籌集了約600萬美元。這些戰略舉措旨在加強Biodexa的產品管道和財務狀況。該公司的證券在納斯達克資本市場上交易，股票代碼爲 “BDRX”。
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已宣佈完成幾項重大公司交易，並向美國證券交易委員會提交了註冊聲明的生效後修正案。該公司已與Emtora Biosciences簽訂了許可和合作協議，獲得雷帕黴素的藥物製劑eRapa的獨家權利，還從Adhera Therapeutics, Inc.收購了化合物託利米酮。此外，Biodexa已完成承保公開募股，籌集了約600萬美元。這些戰略舉措旨在加強Biodexa的產品管道和財務狀況。該公司的證券在納斯達克資本市場上交易，股票代碼爲 “BDRX”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。